TheraVectys, a biotechnology company located in Paris Institut Pasteur, develops new vaccines derived from the DNA Flap Lentivirus technology patented by Pierre Charneau.
Key priorities for the company are to conduct further development in therapeutic areas such as AIDS,Cancer,Hepatitis and Malaria.
Proof of concept studies have been achieved in veterinary applications and will be subject to out-licensing.
